Otten Linda G, Schaffer Michelle L, Villiers Benoit R M, Stachelhaus Torsten, Hollfelder Florian
Department of Biochemistry, University of Cambridge, Cambridge, UK.
Biotechnol J. 2007 Feb;2(2):232-40. doi: 10.1002/biot.200600220.
We report a new format for measuring ATP/[(32)P]pyrophosphate exchange in a higher throughput assay of adenylation domains (A-domains) of non-ribosomal peptide synthetases. These enzymes are key specificity determinants in the assembly line biosynthesis of non-ribosomal peptides, an important class of natural products with an activity spectrum ranging from antibiotic to antitumor activities. Our assay in 96-well format allows the rapid measurement of approximately 1000 data points per week as a basis for precise assessment of the kinetics of A-domains. The assay also allows quantitative high-throughput screening of the substrate specificity of A-domains identifying alternative, promiscuous substrates. We show that our assay is able to give high quality data for the T278A mutant of the A-domain of the tyrocidine synthetase module TycA with a 330-fold lower k(cat)/K(M). The large dynamic range of this assay will be useful for the screening of libraries of mutant A-domains. Finally we describe and evaluate a procedure for the high-throughput purification of A-domains in 96-well format for the latter purpose. Our approach will be of utility for mechanistic analysis, substrate profiling and directed evolution of the A-domains, to ultimately enable the combinatorial biosynthesis of non-natural analogues of non-ribosomal peptides that may have potential as alternative drug candidates.
我们报告了一种新的检测形式,用于在非核糖体肽合成酶腺苷化结构域(A结构域)的高通量检测中测量ATP/[(32)P]焦磷酸交换。这些酶是非核糖体肽流水线生物合成中的关键特异性决定因素,非核糖体肽是一类重要的天然产物,其活性谱涵盖从抗生素到抗肿瘤活性。我们的96孔板检测形式允许每周快速测量约1000个数据点,作为精确评估A结构域动力学的基础。该检测还允许对A结构域的底物特异性进行定量高通量筛选,以识别替代的、混杂的底物。我们表明,我们的检测能够为短杆菌酪肽合成酶模块TycA的A结构域的T278A突变体提供高质量数据,其催化常数/米氏常数(k(cat)/K(M))降低了330倍。该检测的大动态范围将有助于筛选突变A结构域文库。最后,我们描述并评估了一种用于后一目的的96孔板形式A结构域高通量纯化方法。我们的方法将有助于对A结构域进行机理分析、底物分析和定向进化,最终实现非核糖体肽非天然类似物的组合生物合成,这些类似物可能具有作为替代药物候选物的潜力。